159 related articles for article (PubMed ID: 38393969)
1. ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms.
Tian J; Ashique AM; Weeks S; Lan T; Yang H; Chen HH; Song C; Koyano K; Mondal K; Tsai D; Cheung I; Moshrefi M; Kekatpure A; Fan B; Li B; Qurashi S; Rocha L; Aguayo J; Rodgers C; Meza M; Heeke D; Medfisch SM; Chu C; Starck S; Basak NP; Sankaran S; Malhotra M; Crawley S; Tran TT; Duey DY; Ho C; Mikaelian I; Liu W; Rivera LB; Huang J; Paavola KJ; O'Hollaren K; Blum LK; Lin VY; Chen P; Iyer A; He S; Roda JM; Wang Y; Sissons J; Kutach AK; Kaplan DD; Stone GW
Cancer Immunol Res; 2024 May; 12(5):592-613. PubMed ID: 38393969
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of ILT family receptors.
Nakajima H; Asai A; Okada A; Ping L; Hamajima F; Sata T; Isobe K
J Immunol; 2003 Dec; 171(12):6611-20. PubMed ID: 14662864
[TBL] [Abstract][Full Text] [Related]
3. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.
Shiroishi M; Tsumoto K; Amano K; Shirakihara Y; Colonna M; Braud VM; Allan DS; Makadzange A; Rowland-Jones S; Willcox B; Jones EY; van der Merwe PA; Kumagai I; Maenaka K
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8856-61. PubMed ID: 12853576
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules.
Petroff MG; Sedlmayr P; Azzola D; Hunt JS
J Reprod Immunol; 2002; 56(1-2):3-17. PubMed ID: 12106880
[TBL] [Abstract][Full Text] [Related]
7. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
8. Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4.
Wu CL; Svendsen SG; Riviere A; Desgrandchamps F; Carosella ED; LeMaoult J
Hum Immunol; 2016 Sep; 77(9):720-6. PubMed ID: 26874236
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors.
Lepin EJ; Bastin JM; Allan DS; Roncador G; Braud VM; Mason DY; van der Merwe PA; McMichael AJ; Bell JI; Powis SH; O'Callaghan CA
Eur J Immunol; 2000 Dec; 30(12):3552-61. PubMed ID: 11169396
[TBL] [Abstract][Full Text] [Related]
10. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts.
Zhang W; Liang S; Wu J; Horuzsko A
Transplantation; 2008 Oct; 86(8):1125-34. PubMed ID: 18946352
[TBL] [Abstract][Full Text] [Related]
11. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
[TBL] [Abstract][Full Text] [Related]
12. The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma.
Wang L; Fan J; Ye W; Han J; Zhang Y; Zhao L; Duan J; Yin D; Yi Y
Immunol Invest; 2019 Oct; 48(7):704-718. PubMed ID: 31044626
[TBL] [Abstract][Full Text] [Related]
13. ILT4 facilitates angiogenesis in non-small cell lung cancer.
Wang S; Wang J; Gong W; Zhang F; Chen X; Xu H; Han Y; Fu X; Wang L; Li J; Gao A; Sun Y
Cancer Sci; 2024 May; 115(5):1459-1475. PubMed ID: 38433526
[TBL] [Abstract][Full Text] [Related]
14. HLA-G promotes myeloid-derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4.
Köstlin N; Ostermeir AL; Spring B; Schwarz J; Marmé A; Walter CB; Poets CF; Gille C
Eur J Immunol; 2017 Feb; 47(2):374-384. PubMed ID: 27859042
[TBL] [Abstract][Full Text] [Related]
15. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance.
Zhang Y; Lu N; Xue Y; Zhang M; Li Y; Si Y; Bian X; Jia Y; Wang Y
Mol Med Rep; 2012 Apr; 5(4):910-6. PubMed ID: 22246571
[TBL] [Abstract][Full Text] [Related]
16. The role of soluble HLA-G and HLA-G receptors in patients with hematological malignancies after allogeneic stem cell transplantation.
Biedroń M; Rybka J; Wróbel T; Prajs I; Poręba R; Kuliczkowski K
Med Oncol; 2015 Aug; 32(8):219. PubMed ID: 26187179
[TBL] [Abstract][Full Text] [Related]
17. Soluble HLA-G inhibits myeloid dendritic cell function in HIV-1 infection by interacting with leukocyte immunoglobulin-like receptor B2.
Huang J; Burke P; Yang Y; Seiss K; Beamon J; Cung T; Toth I; Pereyra F; Lichterfeld M; Yu XG
J Virol; 2010 Oct; 84(20):10784-91. PubMed ID: 20702625
[TBL] [Abstract][Full Text] [Related]
18. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization.
Dietrich J; Cella M; Colonna M
J Immunol; 2001 Feb; 166(4):2514-21. PubMed ID: 11160312
[TBL] [Abstract][Full Text] [Related]
19. HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j.
Morel E; Bellón T
J Immunol; 2008 Aug; 181(4):2368-81. PubMed ID: 18684926
[TBL] [Abstract][Full Text] [Related]
20. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions.
Saverino D; Fabbi M; Ghiotto F; Merlo A; Bruno S; Zarcone D; Tenca C; Tiso M; Santoro G; Anastasi G; Cosman D; Grossi CE; Ciccone E
J Immunol; 2000 Oct; 165(7):3742-55. PubMed ID: 11034379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
